Last reviewed · How we verify

NCT06147518

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

Status unknown NA Last updated 8 December 2023
What this trial tests

NA trial testing Metformin in Compensated Cirrhosis in 240 participants. Status unknown.

Timeline
20 December 2023
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorInstitute of Liver and Biliary Sciences, India
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment240
Start date20 December 2023
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 70, any sex, with Compensated Cirrhosis or Decompensated Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetes prevalence is increasing among cirrhotics and use of OAD in cirrhotics is limited because of risk of hypoglycaemia and other adverse effects, therefore in this study we would be using OAD in the form of Sitagliptin or Dapagliflozin to look for glycemic response as well as to look for other benefits such as weight reduction and improvement in lipid parameters.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06147518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing